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ABSTRACT: 
Background: Antibody-based immunity to JC polyomavirus (JCV) is not well understood and monoclonal 
Antibodies (mAbs) that functionally neutralize the infectivity of JCV have not been documented.   
Methods: Recombinant JCV  virus-like particles (VLPs) were produced in a baculovirus system, and  
mouse mAbs against this protein generated using standard methods.Six mAbs that bound to VLPs in  
ELISA assays were obtained for further characterization.  
Results:.   Four antibodies recognized epitopes present only in intact VLPs, while the other two antibodie 
s reacted only with denatured VLPs. Five of the six antibodies cross-reacted with VLPs based on JCV’s 
close relative BKV.The only JCV-specific mAb, clone JCV-10.13 (isotype IgG2a) recognized a  
conformational epitope.  This mAb potently neutralized the infectivity of pseudoviruses based on wild- 
Type  JCV genotypes 1A and 2A, but neutralized pseudoviruses based on the distantly related JCV  
genotype 3B very poorly.  JCV-10.13 also neutralized the infectivity of a subset of JCV pseudoviruses 
carrying capsid protein mutations typical of those found in the cerebrospinal fluid of patients suffering from 
 JCV-induced progressive multifocal leukoencephalopathy (PML).  In contrast to JCV-10.13, another  
conformation-specific mAb, JCV-9.16,failed to neutralize any tested JCV variants.  
Conclusions: These data show show that VLP-based ELISAs can detect JCV-binding antibodies that do  
not detectably neutralize the infectivity of JCV. These observations have relevance for developing VLP- 
based vaccines or therapeutic mAbs against JCV.  VLPs from multiple genotypes may be needed to 
formulate a vaccine that could protect against diverse JCV strains circulating in patients with PML.  
Functional neutralization-based serology  will be required for effective validation of candidate JCV VLP 
vaccines and therapeutic mAbs.  
  
CONCLUSIONS:  
(1) VLP-based ELISAs can detect  JCV-binding antibodies that do not  
necessarily neutralize the infectivity of JCV. Therefore, functional neutralization-based 
 serology will be needed to validate candidate JCV VLP vaccines and therapeutic McAbs  
(2) The neutralizing activity of McAbs can be specific for particular genotypes and clinical 
  strains. Hence, VLPs from multiple genotypes may be needed to formulate a vaccine 
 that could protect against diverse JCV strains circulating in patients with progressive 
 multifocal encephalopathy. PML.   
 
RESULTS:  Immunoglobulin isotype determination of the six McAbs raised established that 
one each was IgG1 and IgG2, two were IgG2b,, while the remaining three were IgM. In 
ELISA based binding assays the McAbs bound JCV VLP with mean OD ranging from 0.510 
(JC-3.6) to 2.06 (JC-10.13). Of twelve McAbs to BKV and eleven McAbs to SV40 only one 
BKV antibody (BK-F11) and 3 SV40 antibodies (VP1- F11, H2, I2) bound weakly to JCV 
VLP  (Figure  1). Thus, it is possible to raise species-specific McAbs to different 
polyomaviruses. JC-2.5, JC-3.6, JC 6.7, JC-7.9, and JC-9.16 also showed cross binding to 
BKV pseudocapsids, while JC-3.6 and JC-9.16 also cross bound intact SV40 
pseudocapsids (data not shown). JC-2.5, JC-3.6, JC-9.16 and JC-10.13 recognized only 
intact pseudocapsids, presumably at exposed conformational epitopes. JC-6.7 and JC-7.9 
recognized only denatured JCV, BKV, and SV40 pseudocapsids suggesting the existence 
of linear buried epitopes common to all 3 human polyomavirus species studied. The 
predominance of conformational epitopes has is similar to what has been observed in 
similar studies performed on another structurally similar virus, namely human 
papillomavirus (4). Conformational epitopes are generally more efficient in inducing a potent 
antibody mediated response than linear epitopes. Thus, it has been shown that 
papillomavirus capsomeres (pentameric subcapsid particles produced in E.coli) elicit lower 
antibody titers than intact VLP. On the other hand, papillomavirus capsids can be as 














Figure 1: Binding of anti-BKV, anti-JCV and anti-SV40 monoclonal antibodies to JCV virus like particles (VLPs) 
evaluated by ELISA based binding assays. Optical density values plotted on the Y-axis are mean of duplicate 
values. Hatched bars represent binding of binding after disruption of VLPs in 0.2 M Na2CO3 buffer (pH 10.6) 
containing 0.01 M dithiothreitol.   
 
The only JCV-specific monoclonal antibody clone JCV-10.13 (isotype IgG2a), recognized a 
conformational epitope.  In the Buck Laboratory, this monoclonal antibody potently 
neutralized the infectivity of pseudoviruses based on wild-type JCV genotypes 1A and 2A, 
but neutralization of genotype 3B was poor (Figure 2). JCV-10.13 also neutralized the 
infectivity of a subset of JCV pseudoviruses carrying capsid protein mutations typical of 
those found in the cerebrospinal fluid of patients suffering from PML. In contrast to JCV-
10.13, another conformation-specific mouse monoclonal antibody, JCV-9.16, failed to 
neutralize any tested JCV variants. 
 
 














Figure 2: Neutralizing properties of  McAb JCV-10.13.  EC50 titers are presented numerically (top left) and as a 
bar graph (bottom left) for JCV genotypes 1A (JCVCAG), 2A, 3B, and stereotypical mutants described in the 
cerebrospinal fluid of patients with progressive multifocal encephalopathy (PML).  It can be noted that JCV-10.13 
neutralizes wild-type JCV genotypes 1A (JCVCAG) and 2A (JCV2A) with EC50 titers in the low millions, but 
neutralizes wild-type JCV genotype 3B (JCV3Br) with a titer in the low thousands.  Results of testing against JCV 
3Br are presented at 3 different concentrations, with a dlution as low as 1:100 ((top right and bottom right). With 
respect to PML mutants, 10.13 neutralizes PML variants in the 2A background (267, 269) but doesn't neutralize 
265, which is in the 3B background..  
 
FUTURE PLANS: 
 Existing antibodies to JCV have all been raised in animals and cannot be evaluated for 
 therapeutic efficacy, since there is no experimental mode for PML currently available.  
Therefore, we will seek to produce human JCV  neutralizing monoclonal antibodies, which 
have the potential of being directly transferred to the clinical arena 
a without genetic engineering to eliminate xenoreactivity.  
 
INTRODUCTION: The human antibody response to JCV is incompletely understood and it is not clear why  
some patients develop PML, while others do not. There is also an unmet clinical need to develop therapies  
against PML. Over the past two decades, testing of small molecules as anti-JCV agents has not resulted in  
any notable success for patients with PML. Therefore, it is necessary to further explore the possibility of  
using JCV neutralizing antibodies as a potential immunoprophylaxis and immunotherapeutic option.  To  
date , only limited attention has been paid to the notion of antibody-based therapies for  JCV. This is  
understandable  since the penetration of antibodies into the brain will be limited by the blood brain barrier.  
However, this issue  needs to be re-visited in the era of Nano-medicine which allows therapeutic agents to  
be effectively delivered to specific cell and tissue targets.  Over and above their potential therapeutic use,  
epitope recognition and cross-recognition studies of a panel of JCV monoclonal antibodies will facilitate an 
 understanding of JCV humoral immunity and stimulate the development of vaccines.   
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METHODS: BKV, JCV, and SV40 virus-like particles (VLPs) were prepared using standard methods (1-
6). Hybridomas secreting monoclonal antibodies (McAbs) reactive to VLPs were generated. 
Monoclonal antibody reactivity against both intact and disrupted VLPs was assessed by virus-binding 
ELISA assays. McAbs reacting with intact but not disrupted pseudocapsids were interpreted as 
recognizing conformational epitopes located on the exposed surface of viral capsid (surface epitopes). 
Persistent or residual reactivity after disruption was taken as evidence of linear epitopes. In case of 
reactivity only to disrupted pseudocapsids, epitopes were assumed not to be exposed on the surface 
(buried epitopes). For virus neutralizing assays McAbs were tested as tissue culture supernates diluted 
1:1000. A volume of 5 µl was incubated with 100,000 infectious BK or SV40 virions pseudovirions at 37 
degrees C for 2 hours to neutralize VP-1 epitopes on the viral protein capsid. McAb treated and control 
virions were then used to infect WI-38 cells (BKV, ATCC# VR 837) or CV-1 cells (SV40, Stock #449). 
BKV neutralizing activity was assessed by quantitating BKV DNA  load on day 7 of cultures maintained 
in 25 square cm flasks (5). A reduction in viral DNA yield of >75% compared to control cells was 
accepted as a criterion for McAb neutralizing activity. SV40 neutralizing activity was assessed in 
analogous experiments using quantitative RT-PCR analysis of large Large T-antigen transcripts 
following infection of cells with SV40 virions (a gift from M.J. Tevethia, Pennsylvania State University). 
Results were normalized for levels of cellular TATA-binding protein. Determination of JCV neutralizing 
activity was based on pseudovirion assays developed in the Buck Laboratory. Plots of % inhibition of 
Gaussia luciferase release versus log10 McAb concentration were used to calculate 50% (EC50) and 
90% (EC90) neutralizing concentrations for each McAb. Antibodies were tested against a broad panel 
of JCV reporter vectors corresponding to various natural “wild-type” JCV genotypes (1A, 2A, and 3B), 
and a a representative set of JCV mutant genotypes found in the cerebrospinal fluid of PML patients 
(mutants GCN1, L55F, N265S, S267F, S269F, and Q271K).  
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